Advanced Cell Technology Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular Dystrophy
12/17/2012 9:40:26 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced treatment of the fifth and sixth patients in the company’s European clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), completing the second patient cohort. The patients were injected with 100,000 hESC-derived RPE cells, as compared to 50,000 cells in the first cohort. The outpatient transplantation surgeries were performed successfully and the patients are recovering uneventfully.